Oncolytics Biotech, Inc., a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, recently announced that the company has appointed Dr. Alan Warrander to the role of senior vice president of global licensing and business development. In this position, Dr. Warrander will manage the execution of the global licensing strategy for REOLYSIN®, the company’s proprietary formulation of the human reovirus.
Retaining more than 32 years of experience with biotechnology and pharmaceutical companies, Dr. Warrander most recently served as the director of global licensing at AstraZeneca. Dr. Warrander earned his Ph.D. from the University of Birmingham and his Bachelor of Science degree in chemistry and biochemistry from the University of St. Andrews.
Dr. Brad Thompson, president and chief executive officer of Oncolytics Biotech, stated, “Dr. Warrander will be responsible for the execution of the global licensing strategy for REOLYSIN®.” Dr. Thompson continued, “Having reached an agreement on the design of a Phase III trial examining REOLYSIN® in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers with the U.S. Food and Drug Administration under the Special Protocol Assessment process, and with ongoing Phase II studies in multiple indications, we felt it was important to bring this skill set in house.”